Skip to main content
Caplight Logo









Hervolution Therapeutics

Hervolution Therapeutics

Private
CopenhagenHealthcare & Life Scienceshttps://hervolutiontx.com/

Last Round

Series A

Dec 19, 2024

Total Funding Raised

$28.27M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Hervolution Therapeutics is a biotechnology company that develops novel immunotherapies targeting human endogenous retroviruses (HERVs) to treat cancer, metabolic diseases, and aging-related conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

human endogenous retrovirusesHERVimmunotherapyadenoviral vector therapycancer immunotherapyoff-the-shelf immunotherapyHERV antigensmRNA vector therapydark genomeimmune tolerancepreclinical biotechmetabolic diseaseaging-related diseaseviral immunotherapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hervolution Therapeutics Comparables

Compare Hervolution Therapeutics with similar companies based on industry and business-model similarity.

Hervolution Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ErVimmune
87%
Enara Bio
78%
Epitopea
77%

Hervolution Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 19, 2024
SeedJun 27, 2023
SeedMay 24, 2023
GrantOct 15, 2021

Key People

Founding team and executive leadership

Peter Johannes Holst

Chief Science Officer, Company Owner, CEO & CSO

Executive Team

Anne-Marie Andersson

CTO

Executive Team

Hervolution Therapeutics Investors

Notable investors and investment history

Hervolution Therapeutics investors
InvestorRounds
European Innovation Council FundGrant, Seed, Series A
The Export and Investment Fund of DenmarkSeed
BioInnovation InstituteSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors grew 7815% MoM, from 20 to 1.6K.

  • Apr 27, 2026

    Grew 17% QoQ, from 30 to 35 employees.

Hervolution Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hervolution Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hervolution Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen
Employee Range35
Year Founded2019
Last FundingDec 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?